Presentations will embrace proof on how genomic signatures and next-generation sequencing can enhance the care of sufferers with most cancers

SAN DIEGO, Sept. 5, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a worldwide chief in DNA sequencing and array-based applied sciences, at the moment introduced the upcoming presentation of a number of oncology analysis abstracts at this 12 months’s European Society of Medical Oncology (ESMO) annual assembly, September 9–13 in Paris. The abstracts underscore the worth of next-generation sequencing (NGS) and Illumina’s oncology assays for most cancers analysis and affected person care. 

At ESMO’s annual assembly, happening this week in Paris, Illumina will current numerous abstracts that show the worth of next-generation sequencing and Illumina’s oncology assays for most cancers analysis and affected person care.

“For oncologists, the precedence for every affected person is to supply the very best course of remedy as early as attainable,” stated Dr. Phil Febbo, chief medical officer of Illumina. “There is rising proof that utilizing complete genomic profiling that features pan-cancer and immunotherapy biomarkers can determine the best variety of sufferers who most profit from focused remedy.”

Illumina’s mission in oncology is to assist save lives by enabling personalised most cancers care via genomics, working with clients in each centralized and in-house pathology labs to carry out complete genomic profiling (CGP) of tissue and liquid biopsies to match sufferers to the quickly rising catalogue of focused medication and immunotherapies.

CGP is an NGS method utilizing a single take a look at to evaluate a whole lot of genes—together with related most cancers biomarkers, as established in medical tips and scientific trials—for tumor remedy steerage. Pathologists and oncologists are more and more adopting CGP to boost their skills to determine actionable biomarkers, which may higher match sufferers with precision therapies and scientific trials. Studies present that sufferers who obtain a genomic match with biomarker-driven focused therapies or immunotherapies expertise improved scientific outcomes.

Abstracts accepted for ESMO Congress 2022
One manner of gaining perception into the tumor genome is to determine the mutations used within the analysis of homologous recombination deficiency (HRD). HRD standing has emerged as an essential biomarker in tumors which have excessive ranges of DNA injury, corresponding to ovarian most cancers. However, to allow genomic profiling of ovarian most cancers tumors with indications for PARP inhibitors and predict response to those therapies, labs should reliably assess HRD standing in these tumors. Combining HRD evaluation with a single, complete assay, such because the TruSight™ Oncology 500 (TSO 500) HRD analysis assay, to evaluate a variety of biomarkers supplies outcomes extra shortly than iterative testing and supplies a high-resolution, complete view of the tumor genome. These two abstracts spotlight how labs are combining CGP and HRD to supply a robust take a look at: 

Analytical performance of a next-generation sequencing (NGS) assay kit for assessing homologous recombination deficiency (HRD) from solid tumor samples (925P): This is a poster presentation on a examine accomplished in collaboration with Merck and Myriad Genetics. The information verifies the efficiency of the TSO 500, exhibiting its excessive analytical sensitivity and specificity in detecting BRCA1 and BRCA2 variants (5%–10% restrict of detection) and its correct genomic instability rating (GIS) for HRD standing evaluation in ovarian most cancers. The outcomes present excessive (>95%) concordance in BRCA variant calling and that the GIS had been extremely concordant (R = 0.98) to the reference technique assay. This assay supplies labs with an environment friendly, in-house answer utilizing only one workflow and a restricted pattern dimension, which is able to help scientific analysis and broaden entry to scientific trials for potential precision therapies.

High concordance of different molecular assays in the determination of HRD-associated GIS in high grade epithelial ovarian cancer (572P): This summary presents information ensuing from collaboration between Illumina and the Institute of Pathology on the Technical University of Munich, which included use of the TSO 500 HRD assay.

Large-cohort research present that CGP has the potential to determine related genetic alterations in as much as 90% of samples. Illumina is dedicated to enabling CGP and enhancing analysis important to realizing precision medication in oncology, and collaborations are important in rising the proof of the scientific utility of CGP. Three research being offered at this 12 months’s assembly construct on this proof base:

Tissue and liquid biopsy utilization in advanced NSCLC in a large community US practice (1162P): This is a poster presentation from a real-world utility examine between Illumina and Florida Cancer Specialists & Research Institute. In superior non-small-cell lung most cancers (NSCLC), it is important to have biomarker testing outcomes early. The outcomes confirmed that 42% of stage IV NSCLC sufferers obtained each liquid and tissue testing and had ends in hand previous to first-line remedy extra typically (89.4%) than those that had only a tissue (67%) or liquid (72.5%) tumor take a look at. This is the primary time that a big US neighborhood apply, the place most oncology sufferers are seen, has proven information on how utilizing each tissue and liquid biopsy testing allows quicker turnaround time, guideline-concordant biomarker testing, and biomarker testing outcomes previous to first-line remedy selections.

The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway (503P): This summary presents information ensuing from the Illumina-supported nationwide trial throughout Norwegian hospitals to indicate the potential and worth of CGP in most cancers remedy choice testing.

Exploring different strategies to incorporate germline analysis in tumor whole genome sequencing (1673P):This summary presents information from the Illumina-supported Dutch WIDE examine (quick for “whole-genome sequencing implementation in the usual diagnostics for each most cancers affected person”), accomplished via a collaboration between the Hartwig Medical Foundation, the Netherlands Cancer Institute, and the University Medical Center Utrecht tutorial hospital. 

Recently introduced CGP collaborations
Illumina continues to develop its broad portfolio of oncology partnerships with trade leaders, aimed toward advancing most cancers diagnostics and precision medication. Most lately, Illumina launched the research-use-only TSO 500 HRD test, codeveloped with Merck, to unlock deeper insights concerning the tumor genome. Earlier this 12 months, in collaboration with Bayer, Illumina launched the first companion diagnostic claim for the TruSight Oncology Comprehensive (EU) take a look at enabling focused remedy with Bayer’s Vitrakvi (larotrectinib) for sufferers with NTRK fusion most cancers. Additionally, Illumina and Allegheny Health Network launched a collaboration to judge the impression of in-house CGP to boost affected person care.

About Illumina
Illumina is enhancing human well being by unlocking the facility of the genome. Our deal with innovation has established us as a worldwide chief in DNA sequencing and array-based applied sciences, serving clients within the analysis, scientific, and utilized markets. Our merchandise are used for functions within the life sciences, oncology, reproductive well being, agriculture, and different rising segments. To be taught extra, go to illumina.com and join with us on TwitterFacebookLinkedInInstagram, and YouTube.

Salli Schwartz
US: +01 858 291 6421

Adi Raval
US: +01 202 629 8172

Photo –  https://mma.prnewswire.com/media/1891361/ESMO_Congress_2022.jpg 

Logo – https://mma.prnewswire.com/media/1876671/Illumina_Logo.jpg

SOURCE Illumina, Inc.


Source link

#Latest #Research #ESMO #Congress #Showcases #Impact #Comprehensive #Genomic #Profiling #Cancer #Patients

By Seth A. Dunbar

Seth Dunbar leads clinical research study operations and quality & compliance. He is experienced working with teams to help drug sponsors better leverage eSource data. With 10+ years of experience Seth brings expertise developing eClinical services that integrate data and technology to help companies optimise study execution.

Leave a Reply

Your email address will not be published. Required fields are marked *